RVMD
$95.78-3.51 (-3.54%)
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
Recent News
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
A Look At Revolution Medicines (RVMD) Valuation After Recent Share Price Momentum
Revolution Medicines stock reaction Revolution Medicines (RVMD) has drawn attention after recent trading moves, with the stock closing at $98.40. Investors are weighing this price in relation to its clinical stage oncology profile and current financial metrics. See our latest analysis for Revolution Medicines. While the latest 1 day share price return of 1.24% and 7 day share price return of 3.55% show some recent softness, the 90 day share price return of 22.91% sits alongside a 1 year total...
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.